AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES…
O-RAN ALLIANCE Summit at MWC Barcelona 2026: Capturing AI-Enabled Open RAN Opportunities Today and in Tomorrow’s Open 6G
Operators' strategies on O-RAN introduction and experiences with implementing in live networksViews…
Milano Cortina 2026 Olympic FlameLighting and Handover Ceremonies Information for the Media
22 October 2025 - On Wednesday 26 November 2025 at 11:00 CET,…
NTG Nordic Transport Group A/S – Q3 2025 Conference Call
October 10, 2025 04:00 ET Â | Source: NTG Nordic Transport Group A/S…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025,…
ASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlook
Almere, The Netherlands September 23, 2025, 7:45 a.m. CET ASM International N.V.…
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders Annual General Meeting of September 30, 2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General…
ZETADISPLAY AB (publ) INTERIM REPORT 1 APRIL 30 JUNE 2025 (Q2)
Q2 Interim report April – June 2025 for ZetaDisplay AB (publ) is…
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering…